Matilda ER Tablet is a combination pharmaceutical formulation containing Methylcobalamin (1500 mcg), Vitamin B6 (Pyridoxine, 20 mg), and Folic Acid (5 mg), designed to address deficiencies and support neurological and hematological health. Methylcobalamin, an active form of Vitamin B12, plays a crucial role in nerve cell function, DNA synthesis, and red blood cell production. Vitamin B6 is essential for amino acid metabolism, neurotransmitter synthesis, and maintaining normal nerve function. Folic Acid, a vital B-vitamin, is involved in DNA synthesis, repair, and methylation, and is critical for proper fetal development and prevention of neural tube defects. This extended-release formulation ensures sustained plasma levels, enhancing therapeutic efficacy and patient compliance. Matilda ER Tablet is indicated for the treatment of peripheral neuropathy, megaloblastic anemia due to folate and vitamin B12 deficiency, and other conditions requiring supplementation of these vitamins. It may also be used adjunctively in managing diabetic neuropathy and certain neurological disorders. The combination supports nerve regeneration, reduces symptoms such as numbness and tingling, and promotes hematopoietic function. Administration should be under medical supervision, with dosage adjusted based on clinical response and laboratory parameters. Contraindications include hypersensitivity to any component. Caution is advised in patients with renal impairment or those receiving concurrent vitamin therapy.